Anti-PD-L1 immunotherapy of chronic virus infection improves virus control without augmenting tissue damage by fibrosis
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Casella, Valentina, 1991-
- dc.contributor.author Cebollada Rica, Paula
- dc.contributor.author Argilaguet Marqués, Jordi, 1977-
- dc.contributor.author Vidal Barba, Enric
- dc.contributor.author González Cao, María
- dc.contributor.author Güerri Fernández, Roberto
- dc.contributor.author Bocharov, Gennady A.
- dc.contributor.author Meyerhans, Andreas
- dc.date.accessioned 2024-06-12T15:21:56Z
- dc.date.available 2024-06-12T15:21:56Z
- dc.date.issued 2024
- dc.description.abstract Immunotherapy with checkpoint inhibitors, albeit commonly used against tumors, is still at its infancy against chronic virus infections. It relies on the reinvigoration of exhausted T lymphocytes to eliminate virus-infected cells. Since T cell exhaustion is a physiological process to reduce immunopathology, the reinvigoration of these cells might be associated with an augmentation of pathological changes. To test this possibility, we here analyzed in the model system of chronic lymphocytic choriomeningitis virus (LCMV)-infected mice whether treatment with the checkpoint inhibitor anti-PD-L1 antibody would increase CD8 T cell-dependent fibrosis. We show that pre-existing spleen fibrosis did not worsen under conditions that increase CD8 T cell functionality and reduce virus loads suggesting that the CD8 T cell functionality increase remained below its pathogenicity threshold. These promising findings should further encourage immunotherapeutic trials against chronic virus infections.
- dc.description.sponsorship This work was supported by grants PID2022-141395OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU A way of making Europe, HR17-00199 from the ‘‘la Caixa’’ Foundation and the Russian Science Foundation grant No. 23-11-00116.
- dc.format.mimetype application/pdf
- dc.identifier.citation Casella V, Cebollada Rica P, Argilaguet J, Vidal E, González-Cao M, Güerri-Fernandez R, et al. Anti-PD-L1 immunotherapy of chronic virus infection improves virus control without augmenting tissue damage by fibrosis. Viruses. 2024 May 17;16(5):799. DOI: 10.3390/v16050799
- dc.identifier.doi http://dx.doi.org/10.3390/v16050799
- dc.identifier.issn 1999-4915
- dc.identifier.uri http://hdl.handle.net/10230/60447
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Viruses. 2024 May 17;16(5):799
- dc.relation.projectID info:eu-repo/grantAgreement/ES/3PE/PID2022-141395OB-I00
- dc.rights © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword LCMV
- dc.subject.keyword Anti-PD-L1
- dc.subject.keyword Chronic virus infection
- dc.subject.keyword Fibrosis
- dc.subject.keyword Immunotherapy
- dc.title Anti-PD-L1 immunotherapy of chronic virus infection improves virus control without augmenting tissue damage by fibrosis
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion